Ottobock SE & Co. KGaA: directors' dealings · Germany · BaFin

About Ottobock SE & Co. KGaA

Ottobock SE & Co. KGaA is a German medtech and human-bionics company listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany. The group is best known for its leadership in prosthetics, orthotics, rehabilitation products and related digital and bionic mobility solutions. Its roots go back to Otto Bock’s founding of the business in 1919, and the company later established its long-term operational base in Duderstadt, where its headquarters are now located. Ottobock expanded internationally early on, including the establishment of its first U.S. subsidiary in Minneapolis in 1958. Since 2018, the company has operated as Ottobock SE & Co. KGaA, a structure designed to support long-term growth while preserving the family’s strategic influence. Ottobock’s business model is centered on two core segments. The first, Products & Components (B2B), includes prosthetics components and solutions, neuro-orthotics, digital orthotics and prosthetics, and bionic exoskeletons. The second, Patient Care (B2C), covers a global network of roughly 400 orthopedic patient care centers, where the company provides treatment and user support directly to patients. This dual model gives Ottobock a differentiated position across both industrial medtech supply and clinical care delivery. It also strengthens customer relationships, creates recurring touchpoints with practitioners, and supports a brand built on technical expertise, product performance and innovation. From a competitive standpoint, Ottobock is widely positioned as a global leader in several high-barrier niches, especially advanced prosthetics, neuro-orthotics and human-bionics solutions. Its offering is anchored by a broad portfolio of premium products and services, including components, sockets, knees, hands, wheelchairs, rehabilitation products and exoskeleton technologies. Recent product initiatives have included Speedhand Solution, the next generation of the Exopulse Suit and the active Volton exoskeleton. The group continues to invest in R&D and selected strategic investments, reinforcing its innovation pipeline and supporting future product cycles. Geographically, Ottobock has a broad international footprint, with meaningful activity in Europe, North America and other major healthcare markets. Recent news underscores the company’s momentum. For 2025, Ottobock reported stronger revenue and improved profitability, helped by new product launches, acquisitions and expanding reimbursement coverage in certain markets. The company also stated that it has been listed in the Prime Standard since 9 October 2025 and has been part of the SDAX and TecDAX since the end of 2025. For international equity investors, Ottobock offers exposure to the healthcare technology theme, with a blend of structural growth, innovation-led execution and a German listed profile on the Frankfurt market.